SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ:SQNM) today announced the introduction of its Cancer EpiPanel for high-throughput methylation profiling of DNA samples over hundreds of validated cancer-associated genes. Using Sequenom’s proprietary EpiTYPER™ technology, the pre-designed Cancer EpiPanel, for research use only, offers a first-of-its-kind simplified method of rapid and quantitative methylation profiling of commonly analyzed genes.
